Zomepirac
From Wikipedia, the free encyclopedia
 |
|
|
Zomepirac
|
|
| Systematic (IUPAC) name | |
| 2-[5-(4-chlorobenzoyl)-1,4-dimethyl-pyrrol-2-yl]acetic acid | |
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| Chemical data | |
| Formula | C15H14ClNO3 |
| Mol. mass | 291.729 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
withdrawn |
| Routes | oral |
Zomepirac Sodium is an orally effective NSAID that has antipyretic actions. It was developed by McNeil Pharmaceutical and approved by the FDA in 1980 and marketed under the name Zomax®. However, it was subsequently withdrawn from the market in 1983 due to its tendency to cause anaphylaxis.[1]
Zomepirac was indicated for the management of mild to severe pain.[2]
Zomepirac is the sodium salt of 5-(4-chlorobenzoyl)-1,4 dimethyl-1H-pyrrole-2-acetate dihydrate. It is is a prostaglandin synthetase inhibitor and a pyrrole-acetic acid structurally related to tolmetin sodium.[3] It is more effective than aspirin or codeine alone and is as effective as analgesic combinations containing codeine or other narcotics. Given orally, zomepirac has provided analgesia comparable with usual intramuscular doses of morphine in postoperative pain. With long-term use, neither tolerance to its analgesic effect nor psychological or physical dependence has been demonstrated.[4]
Salicylates: Aspirin (Acetylsalicylic Acid), Diflunisal, Ethenzamide
Arylalkanoic acids: Diclofenac, Indometacin, Sulindac
2-Arylpropionic acids (profens): Carprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Ketorolac, Loxoprofen, Naproxen, Tiaprofenic acid
N-Arylanthranilic acids (fenamic acids): Mefenamic acid
Pyrazolidine derivatives: Phenylbutazone
Coxibs: Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib
Sulphonanilides: Nimesulide
Topically used products: Diclofenac, Flurbiprofen, Ibuprofen, Indometacin, Ketoprofen, Naproxen, Piroxicam
